Background: Genome-wide association studies have successfully identified several common variants showing robust association with schizophrenia. However, individually, these variants only produce a weak effect. To identify genetic variants with larger effect sizes, increasing attention is now being paid to uncommon and rare variants.
G
enome-wide association studies (GWAS), which typically examine millions of common (minor allele frequency [MAF] Ͼ5%) single nucleotide polymorphisms (SNPs), have been highly successful in identifying genetic variants reproducibly associated with complex human traits (1) . Several large-scale GWAS for schizophrenia have been conducted (2) (3) (4) (5) (6) (7) (8) and have provided important findings, for example: 1) the identification of genetic loci such as 6p21-p22.1 (major histocompatibility complex region), 1p21.3 (MIR137) and 18q21.2 (TCF4), associated with schizophrenia at a genome-wide significance level (p Ͻ 5 Â 10 À8 ); 2) the proposal of a genetic architecture for schizophrenia, which is most likely extremely polygenic, involving possibly thousands of common SNPs conferring a disease risk; and 3) support for genetic overlap between schizophrenia and bipolar disorder, based on the overall profiles of common SNPs and top hit genes, such as CACNA1C.
As is the case for most complex diseases, the risk-conferring common SNPs identified so far only have small effect sizes, with odds ratios (OR) predominately ranging from 1.1 to 1.3. Although a recent study indicated that overall profiles of common SNPs could explain a significant part of the variation in liability to schizophrenia (9) , single common SNPs have minimal predictive value and it is uncertain whether they contribute greatly to unraveling the pathogenetic mechanisms that lead to schizophrenia. To discover genetic variants with larger effect sizes, emphasis has shifted toward analyzing uncommon (MAF Ͻ5%) or rare (MAF Ͻ1% or .1%) single nucleotide variants (SNVs), especially those that directly affect protein coding.
Along with a growing interest in rare variants, recent advances in sequencing technology, particularly the emergence of the next-generation sequencing techniques, have enabled us to obtain large volumes of sequence data in a rapid and costeffective manner. A number of novel and interesting findings have been reported in pioneering works that utilized nextgeneration sequencing. In studies of psychiatric and neurodevelopmental diseases, involvement of pathogenic de novo SNVs in intellectual disability, autism spectrum disorder, and schizophrenia has been demonstrated (10) (11) (12) (13) (14) (15) (16) (17) (18) . In studies of nonpsychiatric complex diseases, for example, sick sinus syndrome (19) , inflammatory bowel disease (20) , and celiac disease (21) , uncommon protein-affecting variants with larger effects have been identified by resequencing and fine-mapping analyses of loci detected by GWAS. In a resequencing analysis of candidate genes for impulsivity, an uncommon nonsense variant in HTR2B is reported to be associated with psychiatric diseases marked by impulsivity (22) . The HTR2B nonsense variant reported in that study was exclusive to Finns, highlighting the point that uncommon variants are often population-specific. Therefore, intensive studies using non-Caucasian samples provide an opportunity to discover novel, uncommon risk variants with larger effect sizes that cannot be detected in the Caucasian population, the most extensively investigated population in genetic studies to date.
In addition to analysis of de novo variants, fine mapping of loci previously identified in GWAS, and resequencing of targeted candidate regions, we can now utilize dense catalogs of human genetic variations, including uncommon SNVs created by nextgeneration sequencing projects, such as the 1000 Genomes Project (23) and the Exome Sequencing Project (24), albeit that the latter was confined to European American and African American samples. Uncommon SNVs in these projects were found in seemingly healthy subjects, contrary to extremely rare variants that are robustly associated with psychiatric disorders, such as autism spectrum disorder and schizophrenia, and have been identified exclusively in case samples. However, these uncommon SNVs could represent another class of variants that go some way to provide an explanation for the as yet undiscovered genes responsible for disease heritability. Association analysis of these variants is another promising strategy for identifying genetic risks for common diseases.
In this study, we selected candidate SNVs from the 1000 Genomes Project data, focusing on uncommon, populationspecific, and protein-damaging variants. A total of 47 candidate SNVs satisfied the criteria of being: 1) uncommon; 2) missense, nonsense, or splice site variants predicted to be damaging; 3) Asian-specific; and 4) located in candidate genes for schizophrenia and bipolar disorder. These SNVs were subjected to association analysis using a Japanese case-control cohort, consisting of 2012 patients with schizophrenia and 2781 healthy control subjects. We also performed meta-analysis using genotyping data from an independent Han-Chinese case-control set (results from 333 cases and 369 control subjects, previously reported by another group) and family samples (9 trios and 284 quads, genotyped by our laboratory for this study), to analyze the most significantly associated SNV in a Japanese case-control study.
Methods and Materials

Subjects
We used a Japanese case-control sample, consisting of 2012 unrelated patients with schizophrenia (1111 men, 901 women; mean age 48.1 Ϯ 14.4 years) and 2781 control subjects (1197 men, 1584 women; mean age 43.7 Ϯ 14.4 years). We also used 865 samples from unrelated Japanese patients with bipolar disorder (425 men, 440 women; mean age 50.2 Ϯ 14.4 years; 584 with bipolar I disorder, 276 with bipolar II disorder, and 5 with schizoaffective disorder bipolar type) for additional analysis. Samples from bipolar patients and some of the control participants were recruited through the Collaborative Study of Mood Disorders consortium (25) . All participants were of Japanese origin and were recruited from the Hondo area of Japan. Populations in the Hondo area are known to fall into a single genetic cluster (26) . In our previous analysis using a subset of the same participants, it was shown that Pr(K ¼ 1) (probability that the number of populations present in the sample ¼ 1 [27] ) was larger than .99 (28, 29) and l (genomic control factor [30] ) was 1.074 (31) . These data indicated a negligible population stratification effect in our Japanese samples. All patients had a consensual diagnosis of schizophrenia, according to DSM-IV criteria, from at least two experienced psychiatrists. All healthy control subjects were psychiatrically screened in unstructured interviews. All control subjects and patients gave informed, written consent to participate in the study after being provided with and receiving an explanation of study protocols and objectives.
We also genotyped Han-Chinese samples from mainland China and Taiwan, consisting of 293 schizophrenia pedigrees (1163 subjects: 9 trios and 284 quads, offspring were all affected) (32) . This sample set was collected by the National Institute of Mental Health initiative (http://nimhgenetics.org/). Diagnoses of these samples were made using the Diagnostic Interview for Genetic Studies (33) and the Family Interview for Genetic Studies (34), based on DSM-IV-Text Revision or DSM-IV criteria.
In the meta-analysis, genotyping data collated in a report by Shen et al. (35) was included. In that study, case-control samples of Han-Chinese in Taiwan (333 cases and 369 control subjects) were used. All patients in this cohort were diagnosed by senior psychiatrists using the Structured Clinical Interview for DSM-IV-TR Axis I Disorders. Exclusion criteria included psychosis due to general medical conditions, substance-related psychosis, and mood disorder with psychotic features. Mental status of control participants was evaluated by senior psychiatrists in diagnostic interviews.
This study was approved by the ethics committees of all participating institutes.
Selection of Single Nucleotide Variants
We selected candidate SNVs from the 1000 Genome Project data, released on December 16, 2010 (23) . In this version, 22,891,767 SNVs with PASS flags for quality controls were included. Among them, 11,573,027 SNVs were detectable in Asians, of which 1,911,710 were Asian-specific. From these, we selected variants using the following criteria: 1) missense or splice site variants; 2) variants located within the 1568 genes registered in SZGene (36) or the Bipolar Disorder Gene Database (37) (accessed in January 2011); 3) variant calls with a Phred score Ͼ10, indicating a call accuracy of Ͼ90%; 4) variants with MAF Ͻ5% in Asians; and 5) variants with MAF Ͼ0 and Ͻ5% in the Japanese population. A total of 308 variants remained after the selections. These included one variant located at an essential splice site. There were no nonsense variants. To narrow down the list further, we evaluated functionality of the remaining missense variants, using conservation scores from 46 vertebrate species (phyloP score, collected from the University of California Santa Cruz (UCSC) genome browser [38] [University of California, Santa Cruz, California]) and two programs predicting the impact of missense variants (PolyPhen2 [39] and SIFT [40] ). Finally, 47 SNVs, comprising one essential splice site variant and 46 putatively functional missense variants (a phyloP score Ͼ2, predicted to be probably or possibly damaging by PolyPhen2 and predicted to be damaging by SIFT) were selected. The process of SNV selection is summarized in Table 1 .
Genotyping
Genotyping of Japanese case-control samples was performed using the iPlex Assay on the Sequenom MassARRAY platform (SEQUENOM, San Diego, California), according to the manufacturer's instructions. When primers for the iPlex assay could not be designed or genotyping scatter plots were not well clustered, we first tested the candidate base positions for variant alleles using Sanger sequencing. For this test, we used 384 samples consisting of 128 samples each of patients with schizophrenia, patients with bipolar disorder, and controls subjects. These were a part of the samples described in the Subjects section. Single nucleotide variants validated by this analysis were then genotyped using the TaqMan SNP genotyping assay (Applied Biosystems, Grand Island, New York). To evaluate the genotyping accuracy of the multiplex iPlex Assays, we included two previously analyzed SNPs (rs2279381 and rs3763627 [41] and unpublished data [Kazuo Yamada, MD, PhD, et al.]) that had been genotyped using the TaqMan assay. Genotyping of Chinese schizophrenia pedigree samples collected by the National Institute of Mental Health initiative was performed using the TaqMan assay.
Quality Control and Statistical Analyses
Quality control of genotyping data was performed using the following exclusion criteria: 1) samples with a call rate of Ͻ80%; 2) SNVs with a call rate of Ͻ98%; 3) SNVs showing significant deviation from Hardy-Weinberg equilibrium (HWE) in control samples (p Ͻ .001); and 4) SNVs showing a significant difference of success rate (that is, the proportion of individuals with successful genotype data) between cases and control subjects (p Ͻ .001). Allelic association was analyzed using Fisher's exact test. For analysis of the CACNA1F S671C variant (rs143938580) located on chromosome X, one allele per male sample and two alleles per female sample were counted. Analyses of deviation from HWE, success rate for genotyping, allelic association, and the transmission disequilibrium test (TDT) were performed using PLINK software (version 1.0.7) (42). McNemar's exact test for TDT was performed using the exact2Â2 package for R (43) (http://www.r-project.org/). Meta-analysis of case-control and TDT data sets and evaluation of sample heterogeneity were performed using the casecontrol and TDT meta-analysis package, catmap for R (44) . The Q statistic (45) calculated by catmap was used for the assessment of heterogeneity among data sets. Post hoc calculations of statistical power were performed using the Genetic Power Calculator (http://pngu.mgh.harvard.edu/ $purcell/gpc/) (46) with the multiplicative model.
Results
Allelic Association Analyses
The results of Japanese case-control allelic association analyses are shown in Table 2 , while detailed information about selected SNVs and the filtering criteria are shown in Table 1 . The GRIN3A R480G variant (rs149729514) was most significantly associated with schizophrenia (p ¼ .00042, OR ¼ 1.58; twotailed Fisher's exact test). From the number of SNVs whose association could be tested in this study (43 SNVs), we defined a study-wide significance threshold as .0012 (¼ .05/43). Association of the GRIN3A R480G variant (p ¼ .00042) was more significant than this study-wide significance threshold. Nominal association was observed for
From 47 selected SNVs, we observed no variant alleles for three base positions in our population (ADRA1A R376H: rs140512348, FAT1 T3326A: no rs number, and HDAC9 G32R: rs79608746). One SNV (DDX39B R259C: rs145191873) failed quality control, due to a low call rate. Genotypic distribution of the CD36 P90S variant (rs75326924) in control subjects deviated from HWE, with nominal significance (p ¼ .010). Significant difference in the success rate of genotyping was not observed for any SNVs. The consistency between multiplex iPLEX genotyping in this study and TaqMan genotyping in our previous experiments was Ͼ99.9% for rs2279381 and 100% for rs3763627, proving the accuracy of genotyping by the iPLEX Assay.
Replication Analysis and Meta-Analysis of the GRIN3A R480G Variant
To test the validity of association between GRIN3A R480G variant and schizophrenia, we performed replication and metaanalyses, using two sets of data from independent samples.
In 2009, Shen et al. (35) resequenced GRIN3A using samples from the Han-Chinese population in Taiwan, consisting of 333 patients with schizophrenia and 369 control subjects. They detected the R480G variant as an uncommon SNV, along with a nonsignificant overrepresentation of the G allele (Table 3 , p ¼ .145, OR ¼ 1.52, one-tailed Fisher's exact test). Although it has been demonstrated that the genetic clusters generated by Japanese and Han-Chinese populations are different from each other (26) , MAFs of the GRIN3A R480G variant in our Japanese samples and their Han-Chinese samples from Taiwan were similar (2.1% in Japanese control subjects and 1.9% in Han-Chinese control subjects).
We also analyzed Han-Chinese pedigree samples, consisting of 9 trios and 284 quads with affected offspring. We successfully genotyped 565 out of 577 offspring and their parents and observed a nominally significant overtransmission of the G allele ( Combining the three data sets, meta-analysis further supported association between the R480G variant and schizophrenia (Table 3 and Fig. 1, combined p ¼ 3.3 Â 10 À5 , OR ¼ 1.61). In this meta-analysis, we included all probands from trio and quad samples. This result did not change significantly when we randomly selected one proband from each pedigree (combined p ¼ 6.5 Â 10 À5 , OR ¼ 1.60). As there was no significant heterogeneity among three data sets (Q statistic p ¼ .85), the fixed-effect model was applied for meta-analysis. There is accumulating evidence to support the existence of overlap in the genetic susceptibility to schizophrenia and bipolar disorder (4, 47, 48) . To test whether GRIN3A R480G shows positive association with bipolar disorder, we genotyped samples from Japanese bipolar disorder patients (865 samples). While the G allele, which was overrepresented in schizophrenia, was more frequent in bipolar case samples, we did not observe significant association (p = .138, MAF in cases = 2.72%, OR = 1.3; two-tailed Fisher's exact test). Statistical power obtained from the sample size of bipolar cases and control subjects was 33% for nominal significance (a = .05). Association analysis using combined Japanese schizophrenia and bipolar disorder cases and control subjects (2877 cases and 2781 control subjects) showed studywide significant association (p = .00077, Bonferroni-corrected p = .033. OR = 1.50), but the association was slightly less significant than that observed with schizophrenia.
Discussion
In this study, we performed association analyses of uncommon, putatively functional, and Asian-specific SNVs with schizophrenia. We observed five significantly associated SNVs with ORs ranging from 1.41 to 2.35. Among them, the GRIN3A R480G variant showed the strongest association with study-wide significance (p = .00042, Bonferroni-corrected p = .018). Positive association of the GRIN3A R480G variant was observed in independent Han-Chinese pedigree samples (p = .036). Metaanalysis using these data sets and published data from HanChinese case-control samples collected in Taiwan further supported this association (combined p = 3.3 Â 10 À5 ). On the other hand, we observed no significant association of the GRIN3A R480G variant with bipolar disorder. While calculation of statistical power indicated that the sample size of our bipolar cases was not sufficient to appropriately assess association, it is possible that this variant may be more relevant to schizophrenia than bipolar disorder. The GRIN3A R480G variant was not detected in Caucasian and African American populations (23,24) and thus far seems Asianspecific. However, if aberrant GRIN3A function, driven by genomic variations in this gene, does contribute to the pathogenesis of schizophrenia, other risk variants within this gene could be identified in non-Asian populations (and if so, those variants might be non-Asian specific in some cases).
The association signals in GRIN3A have not been detected with genome-wide significance in large-scale GWAS conducted so far. This is not surprising, considering the sample sizes used for the reported GWAS and the MAF and OR of the GRIN3A R480G variant observed in this study. For example, if there is a common SNP with 10%, 25%, or 50% MAF in complete linkage disequilibrium (LD) with the R480G variant, the OR of this common SNP would be 1.13, 1.05, and 1.03, respectively, and the number of cases required for 80% power should be 29,012, 83,979, and 248,882, respectively. Therefore, the sample sizes used in the reported Chinese (7, 8) and Japanese (49,50) GWAS have not been sufficient to identify common marker SNPs in LD with the GRIN3A R480G variant. Even the largest Caucasian GWAS to date (6) would not have enough power to detect marker SNPs, if other risk-contributing SNVs existed in GRIN3A did not generate ORs and/or MAFs much larger than those of the GRIN3A R480G variant. This point clearly indicates the advantage of direct genotyping of disease riskcontributing SNVs, especially in studies aiming to identify risk variants with moderate effect sizes, using medium-sized samples.
GRIN3A encodes the NR3A subunit of the N-methyl-D-aspartate type glutamate receptor (NMDAR). Involvement of NMDAR hypofunction in the pathophysiology of schizophrenia was first proposed, on the observation that NMDAR antagonists, such as phencyclidine, ketamine, and MK801, induced psychiatric abnormalities that mimic both positive and negative symptoms of schizophrenia (51) . The NMDAR hypofunction theory is supported by various lines of evidence from pharmacologic, genetic, postmortem histopathologic, and brain imaging studies (52) .
N-methyl-D-aspartate type glutamate receptor is a heteromeric tetramer protein, composed of two obligate NR1 subunits and two subunits from the NR2 or NR3 families. NR3A acts in a dominant-negative manner to suppress NMDAR activity (53, 54) . NR3A-containing NMDARs display reduced calcium ions (Ca 2ϩ ) permeability and low sensitivity to magnesium ion (Mg 2ϩ ) blockade (55, 56) .
In postmortem brains of patients with schizophrenia, increased GRIN3A expression in layer V of the dorsolateral prefrontal cortex (57), along with decreased spine density in the same region (58, 59) , were reported. Removal of NR3A increases spine density (56) and promotes synapse maturation and memory consolidation (60, 61) . Male NR3A knockout mice show increased prepulse inhibition, a measure of sensorimotor gating, which is impaired in schizophrenia and other neuropsychiatric disorders (62) . These findings collectively suggest the involvement of aberrant, possibly enhanced, GRIN3A function in the pathophysiology of schizophrenia, while also implying that the R480G variant of GRIN3A promotes a gain of function.
Other significantly associated SNVs are located in FAAH, DNMT1, MYO18B, and CFB. FAAH encodes the integral membrane enzyme fatty acid amide hydrolase. Another missense variant in this gene (P129T) was reported to be associated with drug addiction (63) (64) (65) . DNMT1 encodes DNA (cytosine-5-)-methyltransferase 1, which plays an important role in maintaining methylation patterns in the mammalian genome (66) . MYO18B encodes an unconventional myosin, myosin-XVIIIb. This gene harbors rs5761163, which is one of the most significantly associated SNPs in GWAS, conducted by the International Schizophrenia Consortium (4). It is noteworthy that the MYO18B E559K variant and rs5761163 are in complete LD in the 1000 Genomes Project data. CFB encodes complement factor B, a component of the complement system. This gene resides in the major histocompatibility complex class III region on chromosome 6p21.3, a locus associated with schizophrenia, with genome-wide significance (3) (4) (5) (6) 8) . Nevertheless, association of these variants was only nominal and the significant probability of false positivity should be recognized.
To interpret the results of this study more appropriately, two main limitations need to be considered. First, the number of SNVs analyzed in this study was limited. As a selection criterion for SNVs in this study was location in candidate disease genes, it was not surprising to find association of missense variants in promising genes, such as GRIN3A. Given the poor replication status of candidate gene association studies for schizophrenia and other psychiatric diseases, more comprehensive and hypothesis-free analyses, particularly genome-wide association studies of uncommon and putatively functional variants are warranted, especially if we are to uncover new genes. Second, the statistical power obtained from our samples was insufficient for testing association of rare and uncommon variants with a stringent threshold of significance. While we applied study-wide significance (p Ͻ .0012) defined by the number of investigated SNVs in this study, genome-wide significance (p Ͻ 5 Â 10 À8 ) is needed to demonstrate concrete association. Post hoc statistical power for analysis of the GRIN3A R480G variant, calculated from the overall allele counts used in meta-analysis, was 99.3% for nominal significance (a ¼ .05) and 88.5% for study-wide significance (a ¼ .0012) but only 15.6% for genome-wide significance (a ¼ 5 Â 10 À8 ). Moreover, if we consider our Japanese cohort as a sample set for discovery, the statistical power that can be obtained from both sets of Han-Chinese samples for replication are 62.7, 17.0, and .1% for a levels of .05, .0012, and 5 Â 10 À8 , respectively. To corroborate the association observed in this study, analyses using further independent samples should be conducted.
As that has already been demonstrated in genetic studies of other complex diseases, analysis of uncommon proteindamaging SNVs is a valid method of isolating risk variants with larger effects. The identification of study-wide significant association and the observed ORs of associated SNVs in this study would also support this strategy. More comprehensive genome-wide analysis and replication studies are necessary to overcome the limitations of this study, and they will undoubtedly provide further solid and informative biological insight into the pathophysiology of schizophrenia. This caveat aside, our finding that this putatively functional variant of NR3A, a subunit of the NMDAR, showed significant association with schizophrenia paves the way for functional characterization of this mutation in animal models and sets the stage for the discovery of other uncommon disease-associated variants. 
